Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI vs ARNI + SGLT2i on Mitral Remodeling in HFrEF
NCT07379788Completed
- Sponsor
- Rehab Werida
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Open-label trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Rehab Werida. Primary endpoints: Left Ventricular Ejection Fraction at 6 months, Left Atrial Volume Index at 6 months and 2 more. Started Jan 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07379788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379788.